Zevra Therapeutics Inc. (ZVRA)
NASDAQ: ZVRA
· Real-Time Price · USD
8.57
-0.09 (-1.04%)
At close: May 22, 2025, 3:59 PM
8.88
3.62%
After-hours: May 22, 2025, 07:46 PM EDT
-1.04% (1D)
| Bid | 8.46 |
| Market Cap | 468.6M |
| Revenue (ttm) | 40.59M |
| Net Income (ttm) | -91.99M |
| EPS (ttm) | -1.94 |
| PE Ratio (ttm) | -4.42 |
| Forward PE | 11.78 |
| Analyst | Strong Buy |
| Ask | 9 |
| Volume | 422,010 |
| Avg. Volume (20D) | 534,577 |
| Open | 8.60 |
| Previous Close | 8.66 |
| Day's Range | 8.49 - 8.67 |
| 52-Week Range | 4.20 - 9.76 |
| Beta | 1.87 |
About ZVRA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ZVRA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ZVRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Zevra Therapeutics has released their quartely earnings
on May 13, 2025:
1 week ago
+3.43%
Zevra Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
2 months ago
+5.41%
Zevra Therapeutics shares are trading higher after the company announced it will sell its Pediatric Disease Priority Review Voucher for gross proceeds of $150 million.
2 months ago · seekingalpha.com
Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call TranscriptZevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President ...
